您的瀏覽器並不支援JavaScript,但影響頁面呈現,您仍可瀏覽本網頁!
ACADEMIA SINICA INSTITUTE OF BIOMEDICAL SCIENCES
中文 | home | sitemap | contact背景圖
背景圖 conferences research divisions graduate programs research highlight 背景圖
seminars awards&news job opportunities research resources
  introduction core facilities funding opportunities  

:::

research divisions
____________________

 

 

Epidemiology & Genetics
Joint
Cross Div.
Neuroscience
Corresponding
Cross Div.

Cardiovascular Research
Joint
Cross Div.

Infectious Disease &
Immunology
Cross Div.
Cancer
Joint
Corresponding
Cross Div.

Structural Biology

Research Scientist
Adjunct / Emeritus
Research Divisions information
Hsieh, Patrick Ching-Ho's picture

Hsieh, Patrick Ching-Ho

Associate Research Fellow

 

Specialty:

  1. Stem cells and regenerative medicine
  2. Nanoscience and nanomedicine
  3. Translational Research

M.D. Kaohsiung Medical College
Ph.D. University of Washington, Seattle (Bioengineering)

TEL:   02-27899170

FAX:   02-27858594

E-mail:   phsieh@ibms.sinica.edu.tw

PubMed | Recent Publication | Personal Homepage


Research Description

    Although the field of cardiac stem cell therapy has significantly advanced over the past years, the premise of regenerating or replacing diseased human myocardium with functional tissue remains unsatisfied. The overall objective of our research is to promote myocardial stem cell therapy through nano-/micro-environmental engineering the intramyocardial stem cell niche for endogenous cardiac stem cells to reactivate, proliferate, differentiate and repopulate the diseased myocardium. Using a cardiac specific inducible Cre-Lox transgenic mouse strain, we have found that an endogenous cardiac stem cell pool may contribute to ~15% of new cardiomyocytes in the peri-infarcted area, saturated as early as within the first 2 weeks after infarction. Accordingly, we focus on (1) animal models to identify the source of this cardiac stem cell pool, and (2) methods to engineer the cardiac nano-/micro-environments for augmenting the regenerative signaling for spontaneous repair. We have employed a team approach which brings together people from a broad variety of backgrounds, including stem cell biology and biochemistry, biophysics and biomechanics, materials science and controlled drug/gene delivery, synthetic and biochemical engineering, and clinical medicine. This combination has allowed us to work together and interact in a way traditionally not available at an individual laboratory or program.


Selected Recent Publication

  1. Chen HJ, Chen CH, Chang MY, Tsai DC, Baum EZ, Hariri R, Herzberg U, Hsieh PC*. “Human placenta-derived adherent cells improve cardiac performance in mice with chronic heart failure”. Stem Cells Transl Med. 2015;4:269-75.
  2. Wu JM, Hsueh YC, Ch’ang HJ, Wu LW, Nakauchi H, Hsieh PC*. “Circulating cells contribute to cardiomyocyte regeneration after injury”. Circ Res. 2015;116:633-641.
  3. Hsueh YC, Wu JM, Yu CK, Wu KK, Hsieh PC*. “Prostaglandin E2 promotes post-infarction cardiomyocyte replenishment by endogenous stem cells.” EMBO Mol Med. 2014;6:496-503.
  4. Lin YD, Ko MC, Wu ST, Li SF, Hu JF, Lai YJ, Harn HI, Laio IC, Yeh ML, Yeh HI, Tang MJ, Chang KC, Su FC, Wei EI, Lee ST, Chen JH, Hoffman AS, Wu WT, Hsieh PC*. “A nanopatterned cell-seeded cardiac patch prevents electro-uncoupling and improves the therapeutic efficacy of cardiac repair.” Biomaterials Sci. 2014;2:567-580.
  5. Lai CY, Wu PR, Roffler SR, Lee ST, Hwang SM, Wang SS, Wang K, Hsieh PC*. "The clearance kinetics of biomaterials affects stem cell retention and therapeutic efficacy". Biomacromolecules 2014;15:564-73.
  6. Liao WY, Li HJ, Chang MY, Tang AC, Hoffman AS, Hsieh PC*. “Comprehensive characterizations of nanoparticle biodistribution following systemic injection in mice.” Nanoscale. 2013;5:11079-86.
  7. Chang MY, Yang YJ, Chang CH, Tang AC, Liao WY, Cheng FY, Yeh CS, Lai JJ, Stayton PS, Hsieh PC*. “Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction.” J Control Release. 2013;170:287-294.
  8. Chen CH, Wang SS, Wei EI, Chu TU, Hsieh PC*. “Hyaluronan enhances bone marrow cell therapy for myocardial repair after infarction”. Mol Ther. 2013;21:670-679.
  9. Liu YW, Roan JN, Wang SP, Hwang SM, Tsai MS, Chen JH*, Hsieh PC*. “Xenografted human amniotic fluid-derived stem cell as a cell source in therapeutic angiogenesis.”  Int J Cardiol. 2013;168:66-75.
  10. Tang AC, Chang MY, Tang ZC, Li HJ, Hwang GL, Hsieh PC*. “The treatment of acute thromboembolism in mice using heparin-conjugated carbon nanocapsules”. ACS Nano 2012;6:6099-6107.
  11. Lin YD, Luo CY, Hu YN, Yeh ML, Hsueh YC, Tang MJ, Springer ML, Hsieh PC*. “Nanofibrous scaffolds combined with VEGF delivery creates an intramyocardial microenvironment for arteriogenesis and cardiac regeneration.” Sci Transl Med. 2012;4:146ra109.
  12. Tang ZC, Liao WY, Tang AC, Tsai SJ, Hsieh PC*. “The enhancement of endothelial cell therapy for angiogenesis in hindlimb ischemia using hyaluronan.” Biomaterials. 2011; 32:75-86.
  13. Lin YD, Yeh ML, Yang YJ, Tsai DC, Zhu TY, Shih YY, Chang MY, Liu YW, Tang ACL, Chen TY, Luo CY, Chang KC, Chen JH, Wu HL, Hung TK, Hsieh PC*. “Intramyocardial peptide nanofiber injection improves post-infarction ventricular remodeling and efficacy of bone marrow cell therapy in pigs.” Circulation. 2010;122:S132-S141.
  14. Chan SS, Shueh YZ, Liu YW, Hsieh PC*. “Harnessing endogenous intra- and extra-cardiac stem cells for cardiac regeneration – hope or hype?”. Drug Discovery Today: Therapeutic Strategies. 2009; 6:127-133.
  15. Cheng FY, Wang SP, Su CH, Tsai TL, Wu PC, Shieh DB, Chen JH, Hsieh PC*, Yeh CS*. “Stabilizer-free poly(lactide-co-glycolide) nanoparticles for multimodal biomedical probes.”. Biomaterials. 2008;29:2104-2112.
  16. Hsieh PC, Segers VFM, Davis ME, MacGillivray C, Gannon J, Molkentin JD, Robbins F, Lee RT. “Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury”. Nat Med.2007;13:970-974.